

FOR ANIMAL TREATMENT ONLY
Keep out of reach of children

BRAVECTO®

CHEWABLE ORAL FLEA AND TICK TREATMENT FOR DOGS

Read the entire label before use

Bravecto chewable tablet	Fluralaner (mg)
for very small dogs 2 - 4.5 kg	112.5
for small dogs >4.5 – 10 kg	250
for medium dogs >10 – 20 kg	500
for large dogs >20 – 40 kg	1000
for very large dogs >40 – 56 kg	1400

FOR USE IN DOGS FROM 8 WEEKS OF AGE AND OVER 2kg.

INDICATIONS

For the control of flea and tick infestations on dogs.

- Treats and controls existing flea and tick infestations
- Sustained control of new flea and tick infestations for 3 months
- Treatment and control of Demodicosis caused by *Demodex spp.* mites
- Treatment and control of *Otodectes cynotis* and *Sarcoptes scabiei var canis spp.* mites
- Safe for use in MDR1 breeds
- Safe for use in breeding, pregnant and lactating dogs
- Aids in the control of flea allergy dermatitis
- Highly effective against fipronil resistant fleas

GENERAL INFORMATION

Bravecto contains fluralaner, a systemic insecticide and acaricide with a long duration of action that provides immediate and persistent tick (adult and juvenile) *Haemaphysalis longicornis* (NZ Cattle Tick) and flea (*Ctenocephalides felis*) killing activity for 3 months.

Controlled trials indicate that directly after treatment, Bravecto kills 96.8% of existing ticks on the dog within 8 hours and 100% within 12 hours. At 3 months after treatment, around 97.1% of new ticks are killed within 12 hours.

Directly after treatment, Bravecto kills 99% of fleas on the dog within 8 hours and 100% within 12 hours. At 3 months after treatment, 95.7% of new fleas are killed within 8 hours.

Control of flea infestations and flea allergy dermatitis (FAD)

The flea lifecycle is broken due to the rapid onset of action and the long-lasting efficacy against adult fleas on the animal and the absence of viable egg production. Bravecto reduces the flea challenge experienced by the animal and aids in the treatment strategy for flea allergy dermatitis.

Generalised demodicosis

Bravecto has been shown to be highly effective against generalised demodicosis in a clinical field trial.

Otodectes cynotis and *Sarcoptes scabiei var canis spp.* mites

Bravecto has been shown to be highly effective against *Otodectes cynotis* and *Sarcoptes scabiei var canis spp* mites in clinical field trials.

DOSAGE

By law the user must take due care, obtaining expert advice when necessary, to avoid unnecessary pain and distress when using the product other than as directed on the label.

For oral use only.

Bravecto chewable tablets should be administered in accordance with the following table (corresponding to a dose of 25-56 mg fluralaner/kg body weight within one weight band):

Bodyweight (kg) of dog	Number and strength of tablet to be administered				
	Bravecto 112.5 mg	Bravecto 250 mg	Bravecto 500 mg	Bravecto 1000 mg	Bravecto 1400 mg
2* - 4.5	1				
>4.5 - 10		1			
>10 - 20			1		
>20 - 40				1	
>40 - 56					1

***For use in dogs from 8 weeks of age only.**

ADMINISTRATION

Administer Bravecto chewable tablets at or around the time of feeding. Bravecto is a chewable tablet and is well accepted by most dogs. If the tablet is not taken up voluntarily by the dog it can also be given with food or placed directly into the mouth.

To ensure a therapeutic dose is administered, the chewable tablets should not be broken or divided.

For optimal control of tick and flea infestation, the Bravecto chewable tablet should be administered at 3 monthly intervals. Bravecto chewable tablet can be administered all year round.

CONTRAINDICATIONS

If hypersensitivity to the active substance or to any of the excipients is known or suspected, do not use this product.

The safety has not been established in **puppies less than 8 weeks old and/or dogs weighing less than 2 kg**. The safety has not been established for treatment with this product when administered at intervals **shorter than 8 weeks**.

Information for veterinarians

Fluralaner, like other isoxazoline compounds is highly bound to plasma proteins and might compete with other highly bound medicinal products such as non-steroidal anti-inflammatory drugs (NSAIDs) and the coumarin derivative warfarin. Incubation of fluralaner in the presence of carprofen or warfarin in dog plasma at maximum expected plasma concentrations did not reduce the protein binding of fluralaner, carprofen or warfarin. During laboratory and clinical field testing, no interactions between Bravecto and routinely used veterinary medicinal products were observed.

Safety has been demonstrated in breeding, pregnant and lactating animals treated with overdoses of up to 3 times the maximum recommended dose. Safety has been demonstrated in puppies aged 8-9 weeks and weighing 2.0-3.6 kg treated with overdoses of up to 5 times the maximum recommended dose on three occasions at shorter intervals than recommended (8-week intervals). The product was well tolerated in MDR1-deficient Collies following single oral administration at 3 times the recommended dose.

ADVERSE REACTIONS

Mild and transient gastrointestinal symptoms such as diarrhoea/ vomiting/ inappetence/ drooling related to the route of administration of the product may be observed. If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinarian.

STORAGE

Keep out of the sight and reach of children. Store at room temperature away from foodstuffs in the original package to protect from moisture.

HANDLING PRECAUTIONS

Keep the product in the original packaging until use, in order to prevent children from getting direct access to the product. Do not eat, drink or smoke while handling this product. Wash hands thoroughly with soap and water immediately after use of this product. May be harmful if swallowed.

FIRST AID

If skin irritation occurs, get medical advice. If swallowed and you feel unwell, get medical advice/attention and have product label/leaflet on hand.

DISPOSAL

Dispose of used blister pack by wrapping with paper and putting in household waste. Avoid contamination of any water supply with product or empty container.

See *Safety Data Sheet for further information*. www.msd-animal-health.co.nz.

ACVM Registration No. A11019.

See www.foodsafety.govt.nz for registration conditions.

Bravecto is a registered trademark. © 2016

Registered to:

Schering-Plough Animal Health Ltd

Phone: 0800 800 543

www.msd-animal-health.co.nz

